{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:49:59Z","timestamp":1792000199860,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004889","name":"CHU de Qu\u00e9bec - Universit\u00e9 Laval foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jchromb.2018.12.003","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T12:32:19Z","timestamp":1543926739000},"page":"249-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["An LC-MS\/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5\u03b1-abiraterone, and their inactive glucuronide derivatives"],"prefix":"10.1016","volume":"1104","author":[{"given":"Patrick","family":"Caron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1113-1212","authenticated-orcid":false,"given":"Chantal","family":"Guillemette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2018.12.003_bb0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pros.2990040605","article-title":"New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens","volume":"4","author":"Labrie","year":"1983","journal-title":"Prostate"},{"key":"10.1016\/j.jchromb.2018.12.003_bb0010","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000179775","article-title":"New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist","volume":"18","author":"Labrie","year":"1983","journal-title":"Horm. Res."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrurol.2017.115","article-title":"Prostate cancer: STAMPEDE, LATITUDE and Fernand Labrie's legacy","volume":"14","author":"Tombal","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0020","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14656566.2013.745852","article-title":"Abiraterone acetate for the treatment of prostate cancer","volume":"14","author":"Ryan","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0035","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2017.08.035","article-title":"The phase 3 COU-AA-302 study of Abiraterone acetate plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer: stratified analysis based on pain, prostate-specific antigen, and Gleason score","volume":"74","author":"Miller","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0045","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","article-title":"Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial","volume":"31","author":"Ryan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0050","doi-asserted-by":"crossref","first-page":"R403","DOI":"10.1530\/ERC-17-0155","article-title":"Circulating steroid hormone variations throughout different stages of prostate cancer","volume":"24","author":"Snaterse","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jchromb.2018.12.003_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1530\/ERC-17-0107","article-title":"Testicular vs adrenal sources of hydroxy-androgens in prostate cancer","volume":"24","author":"Zang","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.jchromb.2018.12.003_bb0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature17954","article-title":"Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy","volume":"533","author":"Li","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2018.12.003_bb0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jchromb.2018.12.003_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3986","article-title":"Analytical challenges in quantifying abiraterone with LC-MS\/MS in human plasma","volume":"31","author":"Benoist","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchromb.2017.10.033","article-title":"An LC-MS\/MS method for quantification of the active abiraterone metabolite Delta(4)-abiraterone (D4A) in human plasma","volume":"1068-1069","author":"van Nuland","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0080","unstructured":"Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) Bioanalytical Method Validation, Guidance for Industry, \u2212 U.S., https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf, 2018 ((accessed 9 August 2018))."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.fct.2006.11.006","article-title":"Deconjugation of N-glucuronide conjugated metabolites with hydrazine hydrate--biomarkers for exposure to the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)","volume":"45","author":"Frandsen","year":"2007","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jchromb.2018.12.003_bb0090","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0731-7085(00)00244-2","article-title":"Stability and enzymatic hydrolysis of quaternary ammonium-linked glucuronide metabolites of drugs with an aliphatic tertiary amine-implications for analysis","volume":"22","author":"Kowalczyk","year":"2000","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023218313886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023218313886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T06:40:28Z","timestamp":1565246428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023218313886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":18,"alternative-id":["S1570023218313886"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.12.003","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An LC-MS\/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5\u03b1-abiraterone, and their inactive glucuronide derivatives","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}